摘要
随着现代医学水平以及新生儿重症监护室的发展,早产儿的存活率得到极大的提升,但同时也伴随着部分早产儿慢性肺部疾病发病率的上升,如支气管肺发育不良(BPD),BPD是发生在新生儿特别是早产儿中的一种慢性损伤性肺疾病,受影响的婴儿通常需要长期和反复住院,甚至可能出现肺功能的终身改变,严重影响这部分患儿的生活质量。目前,临床上对于BPD暂无特异性的治疗手段,仍以预防为主,因此,早期识别、早期干预对这部分早产儿尤为重要。因此,这就需要我们找到精准的生物标志物去帮助我们识别这部分患儿,本文将就目前对BPD早期相关生物标志物进行综述。
With the development of modern medicine and neonatal intensive care unit, the survival rate of premature infants has been greatly improved, but it is also accompanied by an increase in the inci-dence of chronic lung diseases in some premature infants, such as bronchopulmonary dysplasia (BPD). BPD is a chronic traumatic lung disease that occurs in newborns, especially premature in-fants. Affected infants usually need to be hospitalized for a long time and repeatedly. There may even be lifelong changes in lung function, seriously affecting the quality of life of these children. At present, there is no specific treatment for BPD in clinic, and prevention is still the main treatment. Therefore, early identification and early intervention are particularly important for this part of premature infants. Therefore, it is necessary for us to find accurate biomarkers to help us identify these children. This article will review the early biomarkers of BPD.
出处
《临床医学进展》
2023年第3期3263-3269,共7页
Advances in Clinical Medicine
